19 oktober, 2015 Navid Soltani

Reverseringsmedel för Pradaxa får FDA-godkännande.

FDA (Food and Drug Administration) har idag accelererat godkännandet av Praxbind (idarucizumab) som är reversingsmedel för Pradaxa (dabigatran) vid akuta situationer när behov finns att reversera Pradaxats anti-koagulativa effekt.

The safety and effectiveness of Praxbind were studied in three trials involving a total of 283 healthy volunteers taking Pradaxa (i.e., people who did not require an anticoagulant). In the healthy volunteers who were given Praxbind, there was an immediate reduction in the amount of Pradaxa in participants’ blood (measured as unbound dabigatran plasma concentration) that lasted for a period of at least 24 hours. In this study, the most common side effect from use of Praxbind was headache.

Another trial included 123 patients taking Pradaxa who received Praxbind due to uncontrolled bleeding or because they required emergency surgery. In this ongoing trial, based on laboratory testing, the anticoagulant effect of Pradaxa was fully reversed in 89 percent of patients within four hours of receiving Praxbind. In this patient trial, the most common side effects were low potassium (hypokalemia), confusion, constipation, fever and pneumonia.

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.

About the Author

Navid Soltani Medicine studerande på Karolinska Institutet.